TP53 and therapy-related myeloid neoplasm: In this perspective, Sperling et al., prompted by the observation of the association between thalidomide analogs exposure and TP53-mutated t-MN onset, showed, in mouse models, a survival advantage in TP53-mutated HSC clones when exposed to Lenalidomide, although without conferring resistance to Pomalidomide.